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oliticians in developed countries 
have secured a certain standard 
of health care for the sick as 
well as vaccination programmes to 
reduce the risk of illness. For some of 
these countries, cancer screening is 
next on the agenda, with breast and 
cervical cancer screening programmes 
at the top of the list. When it comes to 
colorectal cancer (CRC), randomised 
trials of screening with the faecal occult 
blood test (FOBT) have shown that 
such screening reduces CRC incidence 
[1] and mortality [1–3]. Indirect 
evidence suggests that endoscopic 
screening (ﬂ  exible sigmoidoscopy and 
colonoscopy) may be far more effective, 
but results from large-scale randomised 
trials are still awaited [4–7]. 
    In the United States, CRC screening, 
using any of these screening modalities, 
has been recommended for many 
years [8–10]. The European Union 
now encourages its member states to 
initiate CRC screening, provided that 
it is done in an organised fashion and 
linked to quality assurance programmes 
[11]. Although the EU guidelines 
point out that only FOBT screening has 
been proven in randomised trials to 
have an effect on CRC, some member 
states (Poland, Germany, and Italy) 
have gone straight for “gold standard” 
colonoscopy screening without 
evidence from randomised trials 
[12,13]. 
    The ideal screening method has not 
yet been found, and the future may 
see more use of promising screening 
modalities such as stool-based DNA 
tests [14] and virtual colonoscopy [15]. 
At present, however, the fact that these 
newer methods are still at an early 
stage of development may only serve 
as an excuse for politicians to “wait 
and see”, and thus further postpone 
a decision on CRC screening. In this 
essay, we discuss the scientiﬁ  c and 
political controversies surrounding 
the introduction of a national CRC 
screening programme. We argue that it 
is in the best interest of governments to 
fund well-conducted randomised trials 
that can guide their decision making.
    Public Awareness of CRC 
    Enthusiastic health professionals often 
ﬁ  nd politicians and health authorities 
too slow to respond to the considerable 
evidence in favour of CRC screening 
[13], and they may take on a political 
role themselves in promoting their 
good cause. In addition, a number of 
celebrities—including Ronald Reagan, 
Katie Couric (an American television 
personality), and Lynn Faulds Wood 
(a British television presenter)—have 
helped to raise public awareness of 
CRC ([16]; http:⁄⁄www.bowelcancer.
tv/cgi-bin/page.pl). His Holiness, the 
late Pope Paul John II, promoted CRC 
screening by being the ﬁ  rst patron of 
the International Digestive Cancer 
Alliance, with strong support from 
United States Senator Hillary Clinton 
[17]. 
    But while there is growing public 
awareness of CRC, there has been 
disturbingly little public discussion 
about the scientiﬁ  c pros and cons 
of CRC screening compared with 
what some countries have seen for 
breast cancer screening. One of the 
main reasons for nonparticipation in 
CRC screening has been that people 
are not convinced that they will 
gain anything by participating [18]. 
Similarly, the failure of some physicians 
to recommend screening may reﬂ  ect 
a general need for more convincing 
evidence and a convincing presentation 
of such evidence. Women being offered 
mammographic screening for breast 
cancer have expressed a particular 
need for information about logistics 
as well as about false positive and 
negative tests, and they want to play 
an active part in decision making on 
screening [19]. This need for balanced 
information on screening applies to 
other types of cancer screening and 
should be the “standard of care” for 
future cancer screening awareness 
campaigns. 
    By failing to recommend screening, 
physicians representing the medical 
profession may appear divided in their 
view to screen or not to screen, and 
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  Box 1. Introducing a CRC 
Screening Programme: 
The Finnish Approach 
    In 2004, Finland launched a 
randomised, stepwise introduction of 
CRC screening using FOBT (biennial, 
unrehydrated Hemoccult-II). For the 
ﬁ  rst six years of introduction, each age 
cohort is randomised to screening or 
“care as usual” (no screening) at age 
60–64 years. In six years, 50% of the entire 
target population will be covered. This 
provides an opportunity to evaluate 
the programme after ﬁ  ve years and to 
further adjust the screening strategy 
or to implement FOBT screening to 
all Finnish citizens aged 60–69 within 
the ensuing ﬁ  ve years. Presently, 
representatives from the ﬁ  ve Nordic 
countries are collaborating to develop 
the Nordic Initiative on Colorectal Cancer, 
an investigator-initiated protocol with an 
aim to further the scientiﬁ  c knowledge of 
CRC screening.  
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undecided on which method to use, 
although the health problem of CRC 
is recognised by all. In many countries, 
CRC is one of the two most frequently 
encountered cancers for men and 
women collectively. Five-year survival 
is only about 50%, increasing to 80% 
if diagnosed at an early, asymptomatic 
stage [20]. Thus, early diagnosis 
and treatment is the obvious key to 
improved cure and survival. 
    Some enthusiasts initially 
recommending national screening 
programmes with continuous quality 
assurance now accept opportunistic 
screening (i.e., screening done outside 
of a national screening programme), 
since “public health policy has not yet 
included population CRC screening” 
[13]. On the other hand, many doctors 
feel that there are still important 
questions to be answered before 
implementing national screening 
programmes. Besides, some are 
concerned that not enough is being 
done for patients who need basic 
health care rather than preventive 
measures. 
    How Good Is the Evidence 
for Screening?
    So what kind of evidence can we offer 
to increase professional enthusiasm for 
CRC screening? Do we only have the 
support of celebrities and little else? 
    FOBT is the only screening method 
submitted to adequately designed 
randomised trials, which showed 
15%–33% mortality reduction from 
CRC after 8–13 years’ follow-up [1–3]. 
The relative mortality reduction was 
signiﬁ  cant in all three trials, proving 
without doubt that “FOBT screening 
does work”. But how good is this in 
absolute, not relative, terms? With 5% 
lifetime risk of CRC and 50% mortality 
from the disease, the risk of dying from 
CRC is 2.5% without FOBT screening. 
With biennial FOBT screening, this 
may be reduced by 23% for those 
attending, i.e., reduced by 0.6% to 
1.9% if attendance is 100%. About 98% 
of us will die from something else. How 
do you sell such ﬁ  gures both to doctors 
and to the public? 
    In contrast to FOBT, we only have 
case-control studies to support the 
usefulness of endoscopy screening, 
and such studies are particularly prone 
to overestimate the effectiveness of 
screening tests when compared with 
randomised trials [21]. The ﬁ  rst reports 
from the four ongoing randomised 
trials on ﬂ  exible sigmoidoscopy 
screening are expected over the 
course of the next several years [4–7], 
while similar randomised trials on 
colonoscopy screening have not, so far, 
been launched. Mortality reduction 
by colonoscopy screening is expected, 
but not proven, to be much higher 
than the 23% for those attending 
FOBT screening, in addition to an 
incidence reduction expected through 
polypectomies.
    There has been some concern about 
a possible excess number of non-CRC 
deaths in the screening group in CRC 
screening trials [22,23]. In addition, 
a recent 17-year follow-up of the 
Danish FOBT study showed that the 
signiﬁ  cant reduction in mortality seen 
after about ten years could no longer 
be observed, probably due to poorer 
attendance with an increasing number 
of screening rounds [24]. Since high 
attendance rates are crucial for the 
success of screening with the FOBT, 
the best choice among the present CRC 
screening options may differ between 
countries and cultures, thus indicating 
a need for research on CRC screening 
referable to the target population. 
Furthermore, there is only limited 
knowledge about what impact an 
increasing menu of screening services 
might have on the responsibility people 
take for their own health. For example, 
DOI: 10.1371/journal.pmed.0030036.g001
  In the US, the CDC (Centers for Disease Control and Prevention) is promoting CRC 
screening for people over 50 years old 
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patients may abandon healthy lifestyles 
(exercising, eating plenty of fruit and 
vegetables, giving up smoking) if they 
believe that screening will pick up 
cancers at an early stage. 
    How Far Should We Compromise 
on Scientiﬁ  c Proof?
    The crucial question is the following: 
how much evidence (and at what 
level in the well-known hierarchy of 
evidence [http:⁄⁄www.shef.ac.uk/
scharr/ir/units/systrev/hierarchy.
htm]) is required before implementing 
national screening programmes? The 
World Health Organization guidelines 
for screening request evidence for 
mortality and morbidity reduction 
from high-quality randomised 
controlled trials before starting any 
population screening programme [25]. 
In other ﬁ  elds of medicine, such as 
pharmacotherapy, randomised trials 
have been a standard requirement 
for introducing any new drug on the 
market. 
    Many health services have admittedly 
been introduced based on much 
weaker evidence than we now have 
for CRC screening. But historic 
substandards should be no argument 
for turning a blind eye to the need for 
the best-quality evidence or for allowing 
health policy decisions to be based 
more on ideology and convictions than 
science. Also, the concept of pushing 
a screening service onto presumably 
healthy people is quite different from 
establishing a health service that 
people seek when they feel sick. The 
level of evidence should therefore be 
more foolproof for screening services 
than for other services, and the 
evidence should be able to withstand 
debates such as the one surrounding 
mammography. High-quality evidence 
on CRC screening would also help 
to unite the somewhat divergent 
professional views on this intervention. 
  The  Finnish  Model
    We need to recognise that some 
countries feel that the introduction of 
national CRC screening programmes is 
an urgent matter. Ideally, these should 
be rolled out in a stepwise, randomised 
fashion, just as Finland has done (see 
Box 1), allowing evaluation of its FOBT 
screening programme after ﬁ  ve years 
before deciding what their next step 
of action should be [26]. The people 
behind the Finnish strategy deserve 
credit for persuading their politicians 
to choose this cautious, stepwise 
model, and the politicians and health 
authorities deserve credit for listening. 
    In the Finnish model, half of each 
age cohort is randomised to screening 
or no screening. The Finnish model 
must have required a lot of explanation 
to authorities that this approach was 
clearly the best way to proceed. It 
was, of course, risky for politicians to 
voluntarily throw away half (or more) 
of their target candidate supporters 
by declaring, in essence, “We believe 
in CRC screening, but aren’t sure 
about it, and half of you will be offered 
screening while the other half will not”. 
    In contrast to the Finnish approach, 
there have been examples of political 
decisions to simply screen everyone 
or none at all, i.e., to reject the idea 
of large-scale randomised trials. 
This rejection may leave health-care 
providers and doctors with a very 
difﬁ  cult choice: either to go straight 
for national screening or to reject the 
political offer and wait for a new set 
of politicians who may understand the 
need for further randomised trials. 
    Short-Term Gain, Long-Term Pain?
    For those who have experienced 
CRC or have been close to someone 
suffering from it (a considerable 
number in Westernised societies), 
any proven beneﬁ  t from screening 
will do. Furthermore, CRC screening 
may appear politically attractive 
and tempting to politicians when 
campaigning for a general election. 
And cost–beneﬁ  t estimates have even 
suggested that such screening may 
be economically sound and at least as 
cost-effective as established national 
screening programmes (for breast and 
cervical cancer) [27]. 
    But politicians should be concerned 
about whether CRC screening is the 
right way to spend available resources 
and taxpayers’ money for the beneﬁ  t 
of individuals, families, employers, 
and the community. There are still 
few data to guide decisions about CRC 
screening. It is hard to understand 
why politicians are reluctant to invest 
in randomised clinical trials, since the 
results of these will equip them to make 
better political decisions in the end. 
    The alternative to taking a 
ﬁ  rm grip on development toward 
national programmes through the 
funding of large, well-designed 
randomised controlled trials seems 
to be uncontrolled out-of-pocket 
expenditure on sporadic screening, 
which cannot generate any real 
evidence about the effectiveness of 
screening. Any country considering 
national CRC screening can surely 
afford to do its own randomised trials, 
but time is running out. Could it 
be that none of the providers really 
want to know, but prefer to make 
decisions by convictions and “gut 
feelings” for short-term gain? For a 
screening programme to survive over 
time, it has to deliver according to 
expectations. If expectations are not 
based on trials referable to the target 
population, any programme will be 
vulnerable to devastating debates, such 
as those surrounding mammographic 
screening seen in some countries.
    Health policymakers must also 
remain sceptical of the role of celebrity 
endorsements. Communication on 
complex decisions such as cancer 
screening, with an aim to inform rather 
than persuade, is not an obvious task 
for celebrities [28]. Likewise, it is not 
an obvious task for doctors to take 
on the role of politicians. Instead, 
politicians must accept the need 
for more science in their decision 
making. We need more objective facts, 
relevant to the target population, to 
be communicated—and not personal 
convictions that doctors, doctor-
politicians, and politicians only present 
as “facts”. To paraphrase former US 
President Franklin Delano Roosevelt: 
“Look to Finland”.   
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